major histocompatibility complex, class I, L (pseudogene)Genealiases: []
Q-omics provides the consensus-scored HLA-L profile across patient tissues and cancer cell-line models. HLA-L expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, HLA-L is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, HLA-L RNA expression shows 15,386 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KIRC, and UVM as cancer lineages where HLA-L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HLA-L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HLA-L survival associations across molecular data types. HLA-L RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HLA-L RNA expression–survival associations across cancer types. High HLA-L expression shows unfavorable associations in LGG and UVM, but favorable associations in MESO, SKCM, UCEC and KIRC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for HLA-L RNA expression.
This table summarizes HLA-L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HLA-L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HLA-L shows lower tumor expression in LUSC and higher tumor expression in KIRC, HNSC, COAD, STAD and BRCA. The KIRC box plot shows higher HLA-L RNA expression in tumor versus normal tissue (log2 FC = +1.310, t-test p < 0.001).
This table shows molecular features associated with HLA-L in patient tissues and cancer cell lines. In patient samples, HLA-L shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, HLA-L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN.
